pGP-AAV-syn-jGCaMP7c variant 1513-WPRE
PurposeAAV-mediated expression of ultrasensitive protein calcium sensor under the Syn promoter
|Item||Catalog #||Description||Quantity||Price (USD)|
|Plasmid||105321||Standard format: Plasmid sent in bacteria as agar stab||1||$75|
|AAV1||105321-AAV1||100 µL at titer ≥ 7×10¹² vg/mL and Plasmid.||$380|
This material is available to academics and nonprofits only.
- Backbone size w/o insert (bp) 4579
- Total vector size (bp) 5932
Vector typeMammalian Expression, AAV
Growth in Bacteria
Bacterial Resistance(s)Ampicillin, 100 μg/mL
Growth Strain(s)NEB Stable
Copy numberLow Copy
Gene/Insert namejGCaMP7c variant 1513
Alt nameGCaMP3-L59Q E60P T302L R303P M378G K379S D380Y T381R R392G T412N
Alt nameGCaMP3 variant 1513
Alt nameJanelia GCaMP7
SpeciesR. norvegicus (rat), G. gallus (chicken); A. victoria (jellyfish)
Insert Size (bp)1353
- Promoter Synapsin
/ Fusion Protein
- T7 epitope, Xpress tag, 6xHis
- Cloning method Restriction Enzyme
- 5′ cloning site BamHI (not destroyed)
- 3′ cloning site HindIII (not destroyed)
- 5′ sequencing primer ACCACGCGAGGCGCGAGATAG (Common Sequencing Primers)
Terms and Licenses
- Not Available to Industry
- Zeocin® is an InvivoGen trademark.
Information for AAV1 (Catalog # 105321-AAV1) ( Back to top )
Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (#105321). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7c variant 1513-WPRE plasmid DNA.Synapsin-driven jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.
- Volume 100 µL
- Titer ≥ 7×10¹² vg/mL
- Pricing $350 USD for preparation of 100 µL virus + $30 USD for plasmid.
- Storage Store at -80℃. Thaw just before use and keep on ice.
- Shipment Viral particles are shipped frozen on dry ice. Plasmid DNA (≥ 200ng) will also be included in the shipment.
Viral Production & Use
- Packaging Plasmids encode adenoviral helper sequences and AAV rep gene, AAV1 cap gene
- Buffer PBS + 0.001% Pluronic F-68 + 200 mM NaCl
- Serotype AAV1
- Purification Iodixanol gradient ultracentrifugation
Requestor is responsible for compliance with their institution's biosafety regulations. Lentivirus is generally considered BSL-2. AAV is generally considered BSL-1, but may require BSL-2 handling depending on the insert. Biosafety Guide
Viral Quality Control
- Addgene ensures high quality viral vectors by optimizing and standardizing production protocols and performing rigorous quality control (QC) (see a list of our QC assays). The specific QC assays performed varies for each viral lot. To learn which specific QC assays were performed on your lot, please contact us.
- Titer: the exact titer of your sample will be reported on the tube. The titer you see listed on this page is the guaranteed minimum titer. See how titers are measured.
Visit our viral production page for more information.
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
For your Materials & Methods section:pGP-AAV-syn-jGCaMP7c variant 1513-WPRE was a gift from Douglas Kim & GENIE Project (Addgene plasmid # 105321 ; http://n2t.net/addgene:105321 ; RRID:Addgene_105321)
For viral preps, please replace (Addgene plasmid # 105321) in the above sentence with: (Addgene viral prep # 105321-AAV1)
For your References section:High-performance calcium sensors for imaging activity in neuronal populations and microcompartments. Dana H, Sun Y, Mohar B, Hulse BK, Kerlin AM, Hasseman JP, Tsegaye G, Tsang A, Wong A, Patel R, Macklin JJ, Chen Y, Konnerth A, Jayaraman V, Looger LL, Schreiter ER, Svoboda K, Kim DS. Nat Methods. 2019 Jul;16(7):649-657. doi: 10.1038/s41592-019-0435-6. Epub 2019 Jun 17. 10.1038/s41592-019-0435-6 PubMed 31209382